Zealand Pharma AS DR ZLDPY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $8.48
- Day Range
- $9.31–9.31
- 52-Week Range
- $7.75–16.00
- Bid/Ask
- $0.01 / $6,011.35
- Shares Outstanding
- 341.19M
- Market Cap
- $3.29B
- Volume/Avg
- 521 / 649
Key Statistics
- Price/Earnings (Normalized)
- 8.16
- Price/Sales
- 4.57
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 2.51%
Company Profile
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Value
- Total Number of Employees
- 544
- Website
- https://www.zealandpharma.com
Valuation
|
Metric
|
ZLDPY
|
|---|---|
Price/Earnings (Normalized) | 8.16 |
Price/Book Value | 1.17 |
Price/Sales | 4.57 |
Price/Cash Flow | 12.42 |
Price/Earnings
ZLDPY
Financial Strength
|
Metric
|
ZLDPY
|
|---|---|
Quick Ratio | 13.76 |
Current Ratio | 13.98 |
Interest Coverage | 92.71 |
Quick Ratio
ZLDPY
Profitability
|
Metric
|
ZLDPY
|
|---|---|
Return on Assets (Normalized) | 17.40% |
Return on Equity (Normalized) | 18.94% |
Return on Invested Capital (Normalized) | 16.47% |
Return on Assets
ZLDPY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|SPqLKfY | LOCK|%ks<q | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|q!mxvF | LOCK|jgrX | $83B | |||
| argenx SE ADR
ARGX
| LOCK|%#vzpt% | LOCK|$^ | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Y>Lj!@$! | LOCK|VQFm@ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?@H#hfr | LOCK|hGH | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|dJLbhK | LOCK|G&Zx! | $31B | |||
| Moderna Inc
MRNA
| LOCK|Nvdb!H# | LOCK|ngX | $25B | |||
| Incyte Corp
INCY
| LOCK|?^%p$^ | LOCK|v&Y | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|TN?G$r | LOCK|RH# | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<@MCgG% | LOCK|^g | $16B |
United States